Allergan merger brings Pfizer back into dermatology
Several of Allergan's flagship products are in the therapeutic areas of dermatology and aesthetics, including brands such as Botox and the cosmetic treatment Juvéderm.
According to Kalorama Information, Pfizer and Allergan's announced merger at a total enterprise value of approximately $160 billion would bring Pfizer back into a therapeutic area of focus the company had previously eliminated, dermatology. Several of Allergan's flagship products are in the therapeutic areas of dermatology and aesthetics, including brands such as Botox and the cosmetic treatment Juvéderm. The healthcare market researcher's report, World Market for Prescription Dermatological Drugs, represents the ninth time that Kalorama has described the global prescription dermatological drugs market and identified the major factors that may help to shape the market for treatments in the future.
"The tax inversion scrutiny with respect to the proposed merger will get attention; we think there are a number of market considerations behind this action," said Bruce Carlson, Publisher of Kalorama Information. "The dermatology space is fast-growing and some of the top treatments are involved."
Some media accounts have noted opposition to this deal, the latest of which have become known as "tax inversion" deals. The merger would create the world's largest drug company and move Pfizer-Allergan's headquarters to Ireland, where the corporate tax rate is 17-18%. The US corporate rate is 35%.
Should the transaction be completed, Pfizer would regain access to some of the therapeutic areas of focus on which the company had previously cut back. In 2007, Pfizer had discontinued their participation in the dermatology, ophthalmology and gastrorenterology (GI) areas. Allergan's key therapeutic categories are dermatology and aesthetics, eye care, central nervous system (CNS) disorders, women's health and urology, anti-infectives and GI. In defending the deal, Pfizer states that with the merger the company's businesses will be significantly enhanced by the addition of a growing revenue stream from Allergan's brands.
The pharmaceutical industry is facing a tougher environment in general, due to harder regulations for gaining approvals for mainstream products, economic issues, and a dwindling pipeline of new products. Reliance on blockbuster drugs is all but over, causing a shift of focus for many drug research and development entities. By focusing on cosmetic medications, many manufacturers are realizing less scrutiny from the FDA and a growing need in the niche markets such as dermatology. This transition will play a role in the future development of the dermatological industry in the years ahead.
These are dynamic times for the prescription dermatological drug industry. The driving forces for the prescription dermatological drugs market include growth and ageing of the worldwide population. The worldwide market for prescription dermatological drugs encompasses a wide variety of products that treat disorders of the skin, as well as the effects of ageing. Industry consolidation, investments in new technologies, and discovery of genetic links to disease are among the industrywide trends.
World Market for Prescription Dermatological Drugs, 9th Edition, details the various categories of prescription dermatological drugs, describes the worldwide market for prescription dermatological drugs, and identifies major market factors that may help to shape the worldwide market for prescription dermatological drugs in the future.
All market data in the report pertains to the worldwide market at the manufacturers' level. Data are expressed in current US dollars. The base year for data was 2015. Historical data are provided for each of the years 2013 and 2014, and forecast data are provided for each of the years 2015 through 2020. Historical, base year, and forecast data are provided for each market segment. Market shares are provided for each market segment for the 2015 base year. Leading companies in the industry are profiled as well.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance